Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06, FiscalAI reports.
Larimar Therapeutics Price Performance
Shares of NASDAQ:LRMR opened at $3.02 on Monday. The stock has a market cap of $313.73 million, a P/E ratio of -1.55 and a beta of 0.73. The firm has a fifty day moving average price of $2.93 and a 200 day moving average price of $3.76. Larimar Therapeutics has a 1-year low of $1.91 and a 1-year high of $6.42.
Insider Buying and Selling at Larimar Therapeutics
In other Larimar Therapeutics news, Director Thomas Hamilton acquired 70,000 shares of the company's stock in a transaction on Thursday, November 12th. The shares were bought at an average cost of $2.67 per share, for a total transaction of $186,900.00. Following the completion of the purchase, the director owned 70,000 shares in the company, valued at $186,900. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO John B. Jr. Harlow bought 17,800 shares of the firm's stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average price of $2.80 per share, with a total value of $49,840.00. Following the purchase, the chief operating officer directly owned 67,800 shares of the company's stock, valued at approximately $189,840. This trade represents a 35.60% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders purchased 140,810 shares of company stock valued at $381,955. Company insiders own 4.00% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts recently commented on LRMR shares. Leerink Partners started coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They issued an "outperform" rating and a $13.00 target price on the stock. Wall Street Zen cut shares of Larimar Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Finally, Wedbush restated an "outperform" rating on shares of Larimar Therapeutics in a research note on Tuesday, November 10th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Larimar Therapeutics currently has a consensus rating of "Buy" and an average target price of $10.33.
Read Our Latest Report on Larimar Therapeutics
Larimar Therapeutics Company Profile
(
Get Free Report)
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.